Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc. has demonstrated strong revenue performance, with total revenue surpassing consensus estimates by approximately $16 million, including an notable $8 million contribution from its product IBSRELA, showcasing its potential for continued growth. The company’s proactive measures, including investments in patient assistance programs and enhanced engagement with healthcare providers, are expected to bolster prescription volumes and patient adherence for its products, particularly XPHOZAH. Furthermore, data indicating significant improvements in patient outcomes with Tenapanor reinforce the therapeutic efficacy of Ardelyx's offerings, suggesting a solid foundation for future market success and revenue growth.

Bears say

Ardelyx Inc. faces a challenging financial outlook primarily due to a decline in gross to net (GTN) sales percentage for its product Ibsrela, which fell to 31% in 3Q25 from approximately 32.2% in the previous quarter, indicating potential pricing pressure. Additionally, adherence to treatment with phosphate binders is notably low, with 57% of patients in a real-world study reporting non-compliance, which could negatively impact revenue generation for its product Xphozah. Lastly, the absence of fiscal year 2025 guidance contributes to ongoing uncertainty and raises concerns about the company's ability to capitalize on its peak net sales projections exceeding $1 billion for Ibsrela.

Ardelyx (ARDX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.